Literature DB >> 15863318

Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002).

Shoukath M Ali1, Abdul R Khan, Moghis U Ahmad, Paul Chen, Saifuddin Sheikh, Imran Ahmad.   

Abstract

A novel gemcitabine-lipid conjugate 5 was synthesized and tested for its in vivo efficacy and toxicity. Compound 5 was tested in BxPC-3 human pancreatic tumor model in SCID mice and exhibited promising activity and lower toxicity when compared with Gemzar.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15863318     DOI： 10.1016/j.bmcl.2005.03.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

2.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

3.  Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Clin Exp Oncol       Date:  2013

4.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

5.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.

Authors:  Mansi Arora; James M Bogenberger; Amro Abdelrahman; Jennifer L Leiting; Xianfeng Chen; Jan B Egan; Aradhana Kasimsetty; Elzbieta Lenkiewicz; Smriti Malasi; Pedro Luiz Serrano Uson; Bolni Marius Nagalo; Yumei Zhou; Marcela A Salomao; Heidi E Kosiorek; Esteban Braggio; Michael T Barrett; Mark J Truty; Mitesh J Borad
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-21       Impact factor: 3.288

6.  Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2015-01

7.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Res Ther Oncol       Date:  2014-04-09

Review 8.  Pancreatic Cancer Chemoresistance to Gemcitabine.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

9.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Med Chem (Los Angeles)       Date:  2013-05

10.  Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Drug Des Devel Ther       Date:  2016-08-12       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.